Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Evaluation of Response to Stereotactic Radiosurgery in Brain Metastases Using Multiparametric Magnetic Resonance Imaging and a Review of the Literature.

Sawlani V, Davies N, Patel M, Flintham R, Fong C, Heyes G, Cruickshank G, Steven N, Peet A, Hartley A, Benghiat H, Meade S, Sanghera P.

Clin Oncol (R Coll Radiol). 2019 Jan;31(1):41-49. doi: 10.1016/j.clon.2018.09.003. Epub 2018 Sep 28.

PMID:
30274767
2.

High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis.

Ford M, Sahbudin I, Filer A, Steven N, Fisher BA.

Rheumatology (Oxford). 2018 Dec 1;57(12):2244-2246. doi: 10.1093/rheumatology/key234. No abstract available.

PMID:
30107548
3.

Seronegative antibody-mediated neurology after immune checkpoint inhibitors.

Wilson R, Menassa DA, Davies AJ, Michael S, Hester J, Kuker W, Collins GP, Cossins J, Beeson D, Steven N, Maddison P, Rinaldi S, Jacob S, Irani SR.

Ann Clin Transl Neurol. 2018 Mar 25;5(5):640-645. doi: 10.1002/acn3.547. eCollection 2018 May.

4.

Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy.

Harrison SR, Tew A, Steven N, Fisher BA.

Rheumatology (Oxford). 2018 Aug 1;57(8):1497-1499. doi: 10.1093/rheumatology/key080. No abstract available.

PMID:
29617934
5.

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Petrella TM, Robert C, Richtig E, Miller WH Jr, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J.

Eur J Cancer. 2017 Nov;86:115-124. doi: 10.1016/j.ejca.2017.08.032. Epub 2017 Oct 4.

6.

Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study.

Marsden JR, Fox R, Boota NM, Cook M, Wheatley K, Billingham LJ, Steven NM; NCRI Skin Cancer Clinical Studies Group, the U.K. Dermatology Clinical Trials Network and the LIMIT-1 Collaborative Group.

Br J Dermatol. 2017 May;176(5):1148-1154. doi: 10.1111/bjd.15112. Epub 2017 Apr 10.

PMID:
27714781
7.

Therapeutic vaccination strategies to treat nasopharyngeal carcinoma.

Taylor GS, Steven NM.

Chin Clin Oncol. 2016 Apr;5(2):23. doi: 10.21037/cco.2016.03.20. Review.

8.

Research methods to change clinical practice for patients with rare cancers.

Billingham L, Malottki K, Steven N.

Lancet Oncol. 2016 Feb;17(2):e70-e80. doi: 10.1016/S1470-2045(15)00396-4. Review.

PMID:
26868356
9.

Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study.

Johnson P, Challis R, Chowdhury F, Gao Y, Harvey M, Geldart T, Kerr P, Chan C, Smith A, Steven N, Edwards C, Ashton-Key M, Hodges E, Tutt A, Ottensmeier C, Glennie M, Williams A.

Clin Cancer Res. 2015 Mar 15;21(6):1321-8. doi: 10.1158/1078-0432.CCR-14-2355. Epub 2015 Jan 14.

10.

Robo4 vaccines induce antibodies that retard tumor growth.

Zhuang X, Ahmed F, Zhang Y, Ferguson HJ, Steele JC, Steven NM, Nagy Z, Heath VL, Toellner KM, Bicknell R.

Angiogenesis. 2015 Jan;18(1):83-95. doi: 10.1007/s10456-014-9448-z. Epub 2014 Oct 28.

PMID:
25348086
11.

Merkel cell polyomavirus small T antigen mediates microtubule destabilization to promote cell motility and migration.

Knight LM, Stakaityte G, Wood JJ, Abdul-Sada H, Griffiths DA, Howell GJ, Wheat R, Blair GE, Steven NM, Macdonald A, Blackbourn DJ, Whitehouse A.

J Virol. 2015 Jan;89(1):35-47. doi: 10.1128/JVI.02317-14. Epub 2014 Oct 15.

12.

A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT, Rickinson AB, Steven NM.

Clin Cancer Res. 2014 Oct 1;20(19):5009-22. doi: 10.1158/1078-0432.CCR-14-1122-T. Epub 2014 Aug 14.

13.

Expanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions.

Khan MW, Curbishley SM, Chen HC, Thomas AD, Pircher H, Mavilio D, Steven NM, Eberl M, Moser B.

Front Immunol. 2014 Jul 23;5:344. doi: 10.3389/fimmu.2014.00344. eCollection 2014.

14.

Inflammatory cell distribution in primary merkel cell carcinoma.

Wheat R, Roberts C, Waterboer T, Steele J, Marsden J, Steven NM, Blackbourn DJ.

Cancers (Basel). 2014 May 6;6(2):1047-64. doi: 10.3390/cancers6021047.

15.

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R.

Clin Cancer Res. 2014 Apr 15;20(8):2192-204. doi: 10.1158/1078-0432.CCR-13-2200. Epub 2014 Feb 21.

16.

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C.

Ann Oncol. 2014 Mar;25(3):700-6. doi: 10.1093/annonc/mdt580. Epub 2014 Feb 6.

17.

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H.

Cancer Chemother Pharmacol. 2013 May;71(5):1191-9. doi: 10.1007/s00280-013-2113-1. Epub 2013 Feb 20.

PMID:
23423489
18.

Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.

Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT.

Cancer Res. 2013 Mar 15;73(6):1676-88. doi: 10.1158/0008-5472.CAN-12-2448. Epub 2013 Jan 24.

19.

Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.

Simpson AA, Mohammed F, Salim M, Tranter A, Rickinson AB, Stauss HJ, Moss PA, Steven NM, Willcox BE.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21176-81. doi: 10.1073/pnas.1108422109. Epub 2011 Dec 12.

20.

Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men.

Ajja R, Lee DC, Sui X, Church TS, Steven NB.

Am J Cardiol. 2011 Nov 15;108(10):1438-42. doi: 10.1016/j.amjcard.2011.06.067. Epub 2011 Aug 23.

21.

Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma.

Steele JC, Rao A, Marsden JR, Armstrong CJ, Berhane S, Billingham LJ, Graham N, Roberts C, Ryan G, Uppal H, Walker C, Young LS, Steven NM.

Gene Ther. 2011 Jun;18(6):584-93. doi: 10.1038/gt.2011.1. Epub 2011 Feb 10.

PMID:
21307889
22.

A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation.

Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, Tanday MK, Wilson AD, Middeldorp JM, Amlot PL, Steven NM.

Transplantation. 2009 Oct 27;88(8):1025-9. doi: 10.1097/TP.0b013e3181b9d918.

PMID:
19855249
23.

The use of herbal medicines by people with cancer in the UK: a systematic review of the literature.

Gratus C, Damery S, Wilson S, Warmington S, Routledge P, Grieve R, Steven N, Jones J, Greenfield S.

QJM. 2009 Dec;102(12):831-42. doi: 10.1093/qjmed/hcp137. Epub 2009 Oct 1. Review.

PMID:
19797394
24.

The use of herbal medicines by people with cancer: a qualitative study.

Gratus C, Wilson S, Greenfield SM, Damery SL, Warmington SA, Grieve R, Steven NM, Routledge P.

BMC Complement Altern Med. 2009 May 14;9:14. doi: 10.1186/1472-6882-9-14.

25.

Antibiotics for the prevention of febrile neutropenia.

Pascoe J, Steven N.

Curr Opin Hematol. 2009 Jan;16(1):48-52. doi: 10.1097/MOH.0b013e32831ac543. Review.

PMID:
19057204
26.

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, Adams DH.

Hepatology. 2009 Jan;49(1):124-32. doi: 10.1002/hep.22626.

PMID:
18980227
27.

Tumor stroma as a target in cancer.

Ahmed F, Steele JC, Herbert JM, Steven NM, Bicknell R.

Curr Cancer Drug Targets. 2008 Sep;8(6):447-53. Review.

PMID:
18781891
28.

Proteomic profiling of urine for the detection of colon cancer.

Ward DG, Nyangoma S, Joy H, Hamilton E, Wei W, Tselepis C, Steven N, Wakelam MJ, Johnson PJ, Ismail T, Martin A.

Proteome Sci. 2008 Jun 16;6:19. doi: 10.1186/1477-5956-6-19.

29.

Expression and function of T cell homing molecules in Hodgkin's lymphoma.

Machado L, Jarrett R, Morgan S, Murray P, Hunter B, Hamilton E, Crocker J, Thomas W, Steven N, Ismail T, Chapman A, Adams DH, Lee SP.

Cancer Immunol Immunother. 2009 Jan;58(1):85-94. doi: 10.1007/s00262-008-0528-z. Epub 2008 May 17.

PMID:
18488221
30.

Consensus of the 'Malasars' traditional aboriginal knowledge of medicinal plants in the Velliangiri holy hills, India.

Ragupathy S, Steven NG, Maruthakkutti M, Velusamy B, Ul-Huda MM.

J Ethnobiol Ethnomed. 2008 Mar 27;4:8. doi: 10.1186/1746-4269-4-8.

31.

Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells.

Hart DP, Xue SA, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B, Lee SP, Steven N, Morris EC, Stauss HJ.

Gene Ther. 2008 Apr;15(8):625-31. doi: 10.1038/sj.gt.3303078. Epub 2008 Feb 28.

PMID:
18305579
32.

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.

Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE.

Cancer Immunol Immunother. 2008 Jul;57(7):977-86.

PMID:
18060404
33.

Rational selection of patients for antibacterial prophylaxis after chemotherapy.

Cullen MH, Billingham LJ, Gaunt CH, Steven NM.

J Clin Oncol. 2007 Oct 20;25(30):4821-8.

PMID:
17947731
34.

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC.

Clin Cancer Res. 2006 Nov 15;12(22):6737-47.

35.

The potential of adoptive transfer of immunity for reducing post transplant Epstein-Barr virus-associated disease.

Steven N.

Curr Opin Infect Dis. 1999 Dec;12(6):585-91. No abstract available.

PMID:
17035825
36.

Antibacterial prophylaxis in patients with cancer and neutropenia.

Freifeld AG, Sepkowitz KA, Martino P, Steven N, Billingham L, Cullen M, Baden LR.

N Engl J Med. 2006 Jan 5;354(1):90-4; author reply 90-4. No abstract available.

PMID:
16394310
37.

Management of febrile neutropenia in the United Kingdom: time for a national trial?

Innes H, Billingham L, Gaunt C, Steven N, Marshall E.

Br J Cancer. 2005 Dec 12;93(12):1324-8.

38.

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.

Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group.

N Engl J Med. 2005 Sep 8;353(10):988-98.

39.

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

Rea DW, Nortier JW, Ten Bokkel Huinink WW, Falk S, Richel DJ, Maughan T, Groenewegen G, Smit JM, Steven N, Bakker JM, Semiond D, Kerr DJ, Punt CJ.

Ann Oncol. 2005 Jul;16(7):1123-32. Epub 2005 Jun 6.

PMID:
15939714
40.

Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.

Savage P, Gao L, Vento K, Cowburn P, Man S, Steven N, Ogg G, McMichael A, Epenetos A, Goulmy E, Stauss HJ.

Blood. 2004 Jun 15;103(12):4613-5. Epub 2004 Feb 26.

42.

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.

Chakrabarti S, Milligan DW, Pillay D, Mackinnon S, Holder K, Kaur N, McDonald D, Fegan CD, Waldmann H, Hale G, Rickinson A, Steven N.

Blood. 2003 Aug 1;102(3):839-42.

43.

A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens.

Jordan SD, Poole CJ, Archer VR, Steven NM, Burton A.

Cancer Chemother Pharmacol. 2003 Aug;52(2):113-8. Epub 2003 May 29.

PMID:
12783201
45.

T cell selection during the evolution of CD8+ T cell memory in vivo.

Callan MF, Annels N, Steven N, Tan L, Wilson J, McMichael AJ, Rickinson AB.

Eur J Immunol. 1998 Dec;28(12):4382-90.

46.

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.

Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, Steven N, McMichael AJ, Rickinson AB.

J Exp Med. 1998 May 4;187(9):1395-402.

47.

Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.

Blake N, Lee S, Redchenko I, Thomas W, Steven N, Leese A, Steigerwald-Mullen P, Kurilla MG, Frappier L, Rickinson A.

Immunity. 1997 Dec;7(6):791-802.

48.

Epstein-Barr virus latent infection in vivo.

Steven NM.

Rev Med Virol. 1997 Jul;7(2):97-106.

PMID:
10398475
49.

Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.

Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB.

J Exp Med. 1997 May 5;185(9):1605-17.

50.

Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.

Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB.

J Exp Med. 1996 Nov 1;184(5):1801-13.

Supplemental Content

Loading ...
Support Center